Friend or foe? Digoxin for systolic HF ups mortality in cohort study

All-cause mortality rose while HF hospitalizations were unaffected in a community-based study of patients receiving digoxin on top of contemporary HF meds that were available to those in the 1990s-era DIG trial, on which current US and European guidelines sanctioning digoxin in some cases of systolic HF were based.

Source: theHeart.org - September 18, 2013 Category: Cardiology Source Type: news